Page last updated: 2024-10-15
3-hydroxykynurenine and Lassitude
3-hydroxykynurenine has been researched along with Lassitude in 1 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Metabolism of tryptophan through the kynurenine pathway is reduced after a 10-week treatment with a higher dose HC and plays a role in the effect of HC on fatigue and physical functioning in patients with secondary AI." | 9.27 | Hydrocortisone Affects Fatigue and Physical Functioning Through Metabolism of Tryptophan: A Randomized Controlled Trial. ( Bos, EH; Kema, IP; Sorgdrager, FJH; Van Beek, AP; Werumeus Buning, J, 2018) |
| "Metabolism of tryptophan through the kynurenine pathway is reduced after a 10-week treatment with a higher dose HC and plays a role in the effect of HC on fatigue and physical functioning in patients with secondary AI." | 5.27 | Hydrocortisone Affects Fatigue and Physical Functioning Through Metabolism of Tryptophan: A Randomized Controlled Trial. ( Bos, EH; Kema, IP; Sorgdrager, FJH; Van Beek, AP; Werumeus Buning, J, 2018) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Sorgdrager, FJH | 1 |
| Werumeus Buning, J | 1 |
| Bos, EH | 1 |
| Van Beek, AP | 1 |
| Kema, IP | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| A Randomized Double Blind Cross-over Study of the Effects of Low Dose and High Dose Hydrocortisone Replacement Therapy on Cognition, Quality of Life, Metabolic Profile and Somatosensation in Patients With Secondary Adrenal Insufficiency[NCT01546922] | Phase 4 | 63 participants (Actual) | Interventional | 2012-02-29 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Change in Cognition After 10 Weeks of Treatment With a Low Dose of Hydrocortisone Compared to 10 Weeks of Treatment With a High Dose of Hydrocortisone.
"Cognitive domains to be tested: memory, executive functioning, attention and social cognition.~The psychological tests consist of oral and written questions or computer tasks.~Data is given as Z-scores based on normative data. Higher Z-scores represent a better performance." (NCT01546922)
Timeframe: After completion of treatment period 1 (that is after 10 weeks from baseline) and after treatment period 2 (that is after 20 weeks from baseline).
| Intervention | Z-scores based on normative data. (Mean) |
|---|
| RBMT-Immediate Memory | RBMT-Delayed Memory | RBMT-Delayed corrected for immediate memory | 15 Words Test-Short-term memory | 15 Words Test-Total immediate memory | 15 Words Test - Learning Score | 15 Words Test - Delayed Memory | 15 Words Test - Delayed corrected for total memory | 15 Words Test-Recognition | Digit Span forward - Short term memory | Rey Complex Figure - Immediate memory | Rey Complex Figure - Delayed memory | Divided attention-reaction time auditory response | Divided attention-reaction time visual response | Divided attention - Number of omission errors | Divided attention - Number of commission errors | Visual scanning - Reaction time for target stimuli | Visual scanning - Number of omission errors | Visual scanning - Number of commission errors | Alertness - Reaction time tonic alertness | Alertness - Reaction time phasic alertness | Semantic fluency | Phonemic fluency | Digit Span backwards-Working memory | Trail Making Test - Time condition A | Trail Making Test - Time condition B | Trail Making Test - Condition B/A | Social Cognition |
|---|
| High Dose of Hydrocortisone | -0.42 | 0.10 | 0.89 | -0.03 | 0.25 | 0.38 | 0.23 | -0.16 | 0.08 | 0.56 | 1.40 | 1.28 | -0.89 | 0.03 | -0.14 | 0.34 | -0.36 | 0.08 | -0.70 | -0.99 | -1.10 | 0.09 | 0.21 | -0.01 | -0.26 | 0.18 | 0.36 | -0.71 |
,| Low Dose of Hydrocortisone | -0.41 | 0.07 | 0.85 | 0.36 | 0.43 | 0.08 | 0.02 | -0.30 | -0.11 | 0.49 | 1.14 | 1.11 | -0.87 | -0.06 | -0.02 | 0.30 | -0.38 | -0.03 | -0.72 | -0.90 | -1.03 | 0.02 | 0.32 | 0.05 | -0.32 | 0.16 | 0.37 | -0.67 |
Trials
1 trial available for 3-hydroxykynurenine and Lassitude